Optimal pain control requires detailed appraisal of each symptom; in many cases definitive treatment of the underlying cause will be the most effective means of pain control. As an example back pain may be due not only to bone metastases but also enlarging lymph nodes, renal pain or retroperitoneal tumour. Benign causes including degenerative joint disease should also be considered and each cause treated specifically alongside the use of analgesics.
1 Twycross RG. Cancer pain syndromes. In: N SykesMT FallonRB Patt, (eds), Clinical pain management cancer pain.London: Arnold; 2003. p. 3–21.
2.
2 DuPen SL DuPen AR Palissar N Hansberry J Kraybill BM Stillman M. Implementing guidelines for cancer poain management: results of a randomised controlled trial.J Clin Oncol1999; 17: 361–370.
3.
3 Mercadente S Villari P Ferrera P Casuccio A. Optimization of opioid therapy for preventing incident pain associated with bone metastases.J Pain Symptom Manage2004; 28: 505–510.
4.
4 Davis MP Weissman DE Arnold RM. Opioid dose titration for severe cancer pain: a systematic evidence-based review.J Pall Med2004; 7: 462–467.
5.
5 Schiller JH Harrington D Belani CP Langer C Sandler A Krook J. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.N Engl J Med2002; 346: 92–98.
6.
6 Heinemmann V. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.Semin Oncol2002; 29(Suppl. 20): 9–16.
7.
7 Tannock IF de Wit R Berry WR Horti J Pluzanska A Chi KN. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.N Engl J Med2004; 351: 1502–1512.
8.
8 Galbraith SM Duchesne GM. Androgens and prostate cancer: biology, pathology and hormonal therapy.Eur J Cancer1997; 33: 545–554.
9.
9 Wu JS-Y Wong R Johnston M Bezjak A Whelan T. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases.Int J Radiat Oncol Biol Phys2003; 55: 594–605.
10.
10 Sze W-M Shelley MD Held I Wilt TJ Mason MD. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy d a systemic review of randomised trials.Clin Oncol2003; 15: 345–352.
11.
11 Chow EJ Harris K Fan G Tsao M Sze WM. Palliative radiotherapy trials for bone metastases: a systematic review.J Clin Oncol2007; 25: 1423–1436.
12.
12 Patchell RA Tibbs PA Regine WF Payne R Saris S Kryscio RJ. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial.Lancet2005; 366: 643–648.
13.
13 Agarawal JP Swangsilpa T van der Linden Y Rades D Jeremic B Hoskin PJ. The role of external beam radiotherapy in the management of bone metastases.Clin Oncol (R Coll Radiol)2006; 18: 747–760.
14.
14 Rades D Hoskin PJ Stalpers LJ Schulte R Poormans P Veninga T. Short-course radiotherapy is not optimal for spinal cord compression due to myeloma.Int J Radiat Oncol Biol Phys2006; 64: 1452–1457.
15.
15 Roos DE Turner SL O’Brien PC Smith JG Spry NA Burmeister BH. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (TROG 96.05).Radiother Oncol2005; 75: 54–63.
16.
16 Chow E Hoskin PJ Wu J Roos D van der Linden Y Hartsell W. A phase III international randomised trial comparing single with multiple fractions for re-irradiation of painful bone metastases: National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) SC 20.Clin Oncol (R Coll Radiol)2006; 18: 125–128.
17.
17 Mithal N Needham P Hoskin P. Retreatment with radiotherapy for painful bone metastases.Int J Radiat Oncol Biol Phys1994; 29: 1011–1014.
18.
18 Salazar OM Sandhu T da Motta NW Escutia MA Lanzos-Gonzales E Moulle-Sone A. Fractionated half body irradiation (HBI) for the rapid palliation of widespread symptomatic metastatic bone disease: a randomised phase III trial of the International Atomic Energy Agency (IAEA).Int J Radiat Oncol Biol Phys2001; 50: 765–775.
19.
19 Nilsson S Franzen L Parker C Tyrrell C Blom R Tennvall J. Bone-targeted radium-223 in symptomatic, hormone refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.Lancet Oncol2007; 8: 587–594.
20.
20 Bouza C Lopez T Magro A Navalpotro L Amate JM. Efficacy and safety of ballon kyphoplasty in the treatment of vertebral compression fractures: a systematic review.Eur Spine J2006; 15: 1050–1067.
21.
21 Catane R Beck A Inbar Y Rabin T Shabshin N Hengst S. MR-guided focused ultrasound surgery (MRgFUS) for the palliation of pain in patients with bone metastases-preliminary clinical experience.Ann Oncol2006; 18: 163–167.
22.
22 Hoskin PJ. The RIB trial.Clin Oncol2004; 16: 445–446.
23.
23 Lipton A Steger GG Figueroa J Alvarado C Solal-Celigny P Body JJ. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.J Clin Oncol2007; 25: 4431–4437.
24.
24 Donovan-Rodriguez T Dickenson AH Urch C. Gabapentin normalizes spinal neuronal responses that correlate with behaviour in a rat model of cancer-induced bone pain.Anesthesiology2005; 102: 132–140.
25.
25 Palumbo A Bringen S Caravita T Merla E Capparella V Callea V. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.Lancet2006; 367: 825–831.
26.
26 Soutar R Lucraft H Jackson G Reece A Bird J Low E. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma.Clin Oncol2004; 16: 405–413.
27.
27 Takada M Fukuoka M Kawahara M Sugiura T Yokoyama A Yokota S. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited stage small cell lung cancer: results of the Japan Clinical Oncology Group Study 9104.J Clin Oncol2002; 20: 3054–3060.
28.
28 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL. Phase II placebo-controlled randomised discontinuation trial of sorefinib in patients with metasatic renal cell carcinoma.J Clin Oncol2006; 24: 1–7.
29.
29 Motzer RJ Hutson TE Tomczak P Michaelson MD Bukowski RM Rixe O. Sunitinib versus interferon alfa in metasatic renal cell carcinoma.N Engl J Med2007; 356: 115–124.
30.
30 Prostate Cancer Trialists Collaborative Group. Maximum androgren blockade in advanced prostate cancer: an overview of 33 randomised trials with 3283 deaths in 5710 patients.Lancet1995; 346: 265–269.
31.
31 Miles D Makris A. Guidelines for the use of aromatase inhibitors.Clin Oncol2008; (in press).
